索磷布韦/维帕他韦/伏西瑞韦治疗NS5A抑制剂经治难治性丙肝的真实世界疗效与安全性
这项真实世界研究评估了SOF/VEL/VOX用于NS5A抑制剂经治、伴肝硬化及门脉高压、既往肝移植或严重肝外表现的HCV感染者的疗效与安全性。97例受试者中,意向性分析SVR12为85%,符合方案分析为90%,GT3合并肝硬化者SVR12为90%。治疗总体耐受良好,但晚期肝病患者可发生严重不良事件。
要点
- NS5A抑制剂经治难治性HCV患者中,SOF/VEL/VOX的符合方案SVR12达90%。
- GT3合并肝硬化患者SVR12为90%,基线NS5A耐药相关替换不影响SVR12。
- 晚期肝病患者治疗中可发生严重不良事件,包括肝失代偿和死亡。
核心结论
- 真实世界研究证实SOF/VEL/VOX对NS5A抑制剂经治的难治性HCV患者(含GT3合并肝硬化者)具有高疗效。
- 治疗在多数患者中耐受良好,但晚期肝病患者可能发生严重不良事件。
研究设计与样本
- 真实世界队列研究,通过早期准入计划纳入97例NS5A抑制剂经治的HCV感染者。
- 入组对象包括伴肝硬化及门脉高压、既往肝移植或严重肝外表现者,主要结局为SVR12。
主要发现
- 意向性分析SVR12为85%(82/97),符合方案分析SVR12为90%。
- 符合方案分析中GT1为91%(GT1a 18/18,GT1b 2/4),GT3为89%(59/66),GT6为100%(3/3)。
- GT3合并肝硬化者SVR12为90%,未发现非SVR12的预测因素。
- 发生4例严重不良事件,包括1例死亡和3例肝失代偿事件。
- 基线检测到的NS5A耐药相关替换不影响SVR12。
关键数值与推荐
- 97例受试者中位年龄58岁,82%为男性,78%有肝硬化,61%(46/76)伴门脉高压,18%有既往肝移植史。
- 肝硬化者中96%为Child-Turcotte-Pugh A级,4%为B级;72%为GT3,其中76%合并肝硬化。
临床怎么用
- 对于NS5A抑制剂经治、含GT3合并肝硬化等难治特征的HCV患者,SOF/VEL/VOX是可考虑的高效挽救方案。
- 治疗晚期肝病患者时应密切监测严重不良事件,包括肝失代偿。
局限性
- 原文未报告随机对照设计,为真实世界早期准入队列,样本量97例。
- 原文未报告对照组的比较数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In clinical trials, hepatitis C virus (HCV) salvage treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) achieved an SVR12 rate of >95% in NS5A-experienced participants. Lower SVR12 rates have been reported in real-world studies, particularly for genotype (GT)3 infection and cirrhosis. We determined the efficacy and safety of SOF/VEL/VOX in a large real-world cohort. METHODS: We assessed the efficacy of salvage SOF/VEL/VOX for HCV infection in NS5A-inhibitor experienced participants with cirrhosis and portal hypertension, prior liver transplantation (LT) or severe extra-hepatic manifestations. SOF/VEL/VOX was available via an early access program. The primary outcome was SVR12. Secondary outcome was frequency of adverse events (AE). FINDINGS: Ninety-seven participants were included. Median age was 58, 82% were male, 78% had cirrhosis, most with portal hypertension (61%, n = 46/76), and 18% had prior-LT. Of the cirrhotic participants, 96% were Child-Turcotte-Pugh class A, and 4% were class B. Of the 72% with GT3, 76% were also cirrhotic. By intention-to-treat analysis, SVR12 rate was 85% (n = 82/97). Per protocol, the SVR12 rate was 90%, including 91% in GT1 (GT1a n = 18/18, GT1b n = 2/4), 89% in GT3 (n = 59/66) and 100% in GT6 (n = 3/3). SVR12 in participants with GT3 and cirrhosis was 90%. No predictors of non-SVR12 were identified. There were 4 serious AEs including 1 death and 3 hepatic decompensation events. NS5A resistance-associated substitutions detected at baseline did not affect SVR12. CONCLUSIONS: This real-world study confirms high efficacy of SOF/VEL/VOX for the treatment of difficult-to-cure NS5A-inhibitor experienced patients, including those with GT3 and cirrhosis. Treatment was well tolerated in most; however, serious AEs can occur in those with advanced liver disease.
引用
- Papaluca T, Roberts SK, Strasser SI, et al. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics. Clin Infect Dis. 2021. PMID: 32887983. doi:10.1093/cid/ciaa1318
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。